Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 10OTHER 6NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Mouth Neoplasms 2Laryngeal Neoplasms 2Carcinoma 2Squamous Cell Carcinoma of Head and Neck 1Sinonasal Squamous Cell Carcinoma 1Oropharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Gliosarcoma 1Glioblastoma 1Eyelid Squamous Cell Carcinoma 1Colorectal Neoplasms 1Adrenocortical Carcinoma 1

Interventions

Cisplatin 23Radiotherapy 22Cetuximab 17Magnetic Resonance Spectroscopy 12Radiotherapy, Intensity-Modulated 10Fluorouracil 10Specimen Handling 9Platinum 91,2-diaminocyclohexaneplatinum II citrate 9pembrolizumab 8Erlotinib Hydrochloride 8Docetaxel 8Carboplatin 8Paclitaxel 7Biopsy 7Bevacizumab 7Radiation 5(225)Ac-DOTA-c(RGDyK) 5Hydroxyurea 4Gefitinib 4Radiosurgery 3Immunoglobulin G 3Disulfides 3Chemotherapy, Adjuvant 3Capecitabine 3ixabepilone 2dehydroftorafur 2atezolizumab 2aldesleukin 2Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Squamous Cell Carcinoma of Head and Neck × cemiplimab × Clear all
NCT06980038 2026-06-01

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
44 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡